(5-allyloxy-1-cyclobutylmethyl-1H-indol-3-yl)-oxo-acetic acid | 710981-70-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (5-allyloxy-1-cyclobutylmethyl-1H-indol-3-yl)-oxo-acetic acid
• 英文别名: 2-[1-(cyclobutylmethyl)-5-prop-2-enoxyindol-3-yl]-2-oxoacetic acid
• CAS: 710981-70-7
• 化学式: C₁₈H₁₉NO₄
• 分子量: 313.353
• InChiKey: TVDZLGHJDRXSPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  草酰氯 、 5-allyloxy-1-cyclobutylmethyl-1H-indole 以 四氢呋喃 为溶剂， 生成 (5-allyloxy-1-cyclobutylmethyl-1H-indol-3-yl)-oxo-acetic acid
  参考文献：
  名称：

  [EN] ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
  [FR] DERIVES D'ACIDE 1H-INDOL-3-YL GLYOXYLIQUE A SUBSTITUTION ARYLE, ARYLOXY ET ALKYLOXY EN TANT QU'INHIBITEURS DE L'INHIBITEUR DE L'ACTIVATEUR DU PLASMINOGENE-1 (PAI-1)

  摘要：

  公开号：

  WO2004052854A3

文献信息

• Inhibitors Of PAI-1 For Treatment Of Muscular Conditions
  申请人：Crandall LeRoy David

  公开号：US20070203220A1

  公开（公告）日：2007-08-30

  This invention describes novel methods of treating muscle damage, muscle wasting, muscle degeneration, muscle atrophy or reduced rates of muscle repair associated with various conditions such as muscular dystrophy, through the use of small-molecule PAI-1 inhibitors.

  这项发明描述了一种通过使用小分子PAI-1抑制剂治疗与各种情况相关的肌肉损伤、肌肉萎缩、肌肉退化、肌肉萎缩或肌肉修复率降低的新方法，例如肌营养不良。
• Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
  申请人：Wyeth

  公开号：US20040138283A1

  公开（公告）日：2004-07-15

  Compounds of formula I are provided: 1 wherein: R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.

  提供了化学式I的化合物：1其中：R1、R2和R3如此定义，在此定义中，以及使用这些化合物作为纤溶酶原激活抑制剂（PAI-1）的抑制剂和作为治疗成分治疗由纤溶障碍引起的病症的药物组合物和方法，例如深静脉血栓、冠心病和肺纤维化。
• Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
  申请人：Wyeth

  公开号：US07259182B2

  公开（公告）日：2007-08-21

  Compounds of formula I are provided: wherein: R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.

  提供公式I的化合物：其中：R1，R2和R3如此定义，在药物组合物和方法中使用这些化合物作为纤溶酶原激活抑制剂（PAI-1）的抑制剂和治疗性组合物，用于治疗由纤溶异常引起的疾病，例如深静脉血栓形成，冠心病和肺纤维化。
• Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
  申请人：Jennings Dalton Lee

  公开号：US20070259922A1

  公开（公告）日：2007-11-08

  Compounds of formula I are provided: wherein: R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.

  提供了I式化合物，其中：R1、R2和R3如本文所定义，以及使用该化合物作为纤溶酶原激活抑制剂（PAI-1）的抑制剂的药物组合物和方法，以及作为治疗纤溶障碍引起的疾病，例如深静脉血栓、冠心病和肺纤维化的治疗组合物。
• ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
  申请人：Wyeth

  公开号：EP1569901A2

  公开（公告）日：2005-09-07